Cantor Fitzgerald set a $25.00 price target on Impax Laboratories Inc (NASDAQ:IPXL) in a research report report published on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Several other brokerages have also commented on IPXL. BidaskClub lowered Impax Laboratories from a buy rating to a hold rating in a research note on Friday, August 4th. Zacks Investment Research lowered Impax Laboratories from a buy rating to a hold rating in a research note on Monday, July 17th. Royal Bank Of Canada set a $17.00 price target on Impax Laboratories and gave the company a hold rating in a research note on Thursday, August 10th. BMO Capital Markets reaffirmed a hold rating and issued a $16.00 price target on shares of Impax Laboratories in a research note on Friday, June 23rd. Finally, BTIG Research reissued a buy rating and issued a $27.00 price objective (up previously from $20.00) on shares of Impax Laboratories in a research note on Saturday, September 23rd. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. Impax Laboratories currently has a consensus rating of Hold and a consensus target price of $18.92.
Impax Laboratories (NASDAQ:IPXL) traded up 1.19% during midday trading on Tuesday, reaching $21.25. The company’s stock had a trading volume of 2,749,449 shares. The firm’s market capitalization is $1.53 billion. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $25.70. The firm has a 50 day moving average price of $21.43 and a 200 day moving average price of $17.41.
Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. Impax Laboratories had a negative return on equity of 15.36% and a negative net margin of 10.10%. Impax Laboratories’s quarterly revenue was up 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.21 EPS. On average, analysts predict that Impax Laboratories will post $0.70 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio raised its position in shares of Impax Laboratories by 12.7% during the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after acquiring an additional 780 shares during the last quarter. Appleton Partners Inc. MA bought a new stake in shares of Impax Laboratories during the second quarter worth $191,000. Advisory Services Network LLC bought a new stake in shares of Impax Laboratories during the second quarter worth $207,000. Virtu KCG Holdings LLC bought a new stake in shares of Impax Laboratories during the second quarter worth $231,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Impax Laboratories by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 171 shares during the last quarter. Institutional investors own 86.26% of the company’s stock.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc and related companies with our FREE daily email newsletter.